Home:
PCU 4|2002: Leonard
G Gomella, MD, FACS: Select Publications
Select publications
Carter HB et al. Expectant management of nonpalpable prostate
cancer with curative intent: Preliminary results. J Urol
2002;167(3):1231-4. Abstract
Djavan B et al. Repeat prostate biopsy: Who, how and when?
A review. Eur Urol 2002;42(2):93. Abstract
Djavan B et al. Safety and morbidity of first and repeat
transrectal ultrasound guided prostate needle biopsies: Results
of a prospective European prostate cancer detection study. J
Urol 2001;166(3):856-60. Abstract
El-Gabry EA et al. Undetectable prostate-specific antigen
response with bicalutamide withdrawal phenomenon. Tech
Urol 2000;6(3):221-2. Abstract
Errejon A, Crawford ED. Monotherapy versus combined androgen
blockade in patients with advanced prostate cancer. Cancer
2002;95(2):209-10. Abstract
Huan SD et al. Antiandrogen withdrawal syndrome with nilutamide.
Urology 1997;49(4):632-4. Abstract
Klotz LH et al. Expectant management with selective delayed
intervention for favorable-risk prostate cancer. Can J
Urol 2002;9(3 Supp 1):2-7. Abstract
Nieh PT. Withdrawal phenomenon with the antiandrogen casodex.
J Urol 1995;153(3 Pt 2):1070- 2;discussion 1072-3. Abstract
Paul R, Breul J. Antiandrogen withdrawal syndrome associated
with prostate cancer therapies: Incidence and clinical significance.
Drug Saf 2000;23(5):381-90. Abstract
Roehl KA et al. Serial biopsy results in prostate cancer
screening study. J Urol 2002;167(6):2435-9. Abstract
Samson DJ et al. Systematic review and meta-analysis of
monotherapy compared with combined androgen blockade for patients
with advanced prostate carcinoma. Cancer 2002;95(2):361-76.
Abstract
Schellhammer PF et al. Prostate specific antigen decreases
after withdrawal of antiandrogen therapy with bicalutamide or flutamide
in patients receiving combined androgen blockade. J Urol
1997;157(5):1731-5. Abstract
Schellhammer PF, Kolvenbag GJ. Serum PSA decline after
Casodex withdrawal. Urology 1994;44(5):790-2. Abstract
Stephenson AJ et al. Utility of PSA doubling time in follow-up
of untreated patients with localized prostate cancer. Urology
2002;59(5):652-6. Abstract
Zietman AL et al. Conservative management of prostate
cancer in the prostate specific antigen era: The incidence and time
course of subsequent therapy. J Urol 2001;166(5):1702-6.
Abstract
|
